BioMarin drug for genetic disorder succeeds in late-stage study

March 21 (Reuters) - BioMarin Pharmaceutical Inc said preliminary data showed its experimental drug met the main goal of reducing blood phenylalanine in patients with a genetic disorder, in a late-stage study.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.